Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis

Author(s): Paola Bertocchi, Chiara Abeni, Fausto Meriggi, Luigina Rota, Anna Rizzi, Brunella Di Biasi, Francesca Aroldi, Chiara Ogliosi, Giordano Savelli, Edoardo Rosso, Alberto Zaniboni.

Journal Name: Reviews on Recent Clinical Trials

Volume 10 , Issue 2 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Metastatic pancreatic cancer still represent one of the most deadly disease for which there are few therapeutic options, especially in second line and beyond setting. Nabpaclitaxel plus gemcitabine activity was demonstrated in first line setting, but there are no clear evidence suggesting its use after that. We report a retrospective data analysis of 23 patients who received nab-paclitaxel plus gemcitabine after first line treatment at our Oncology Department. We observed a significant clinical benefit (43,5%) with a median overall survival of 5 months. In addition, manageable side effects were reported. Our data, despite the small sample, seem to indicate that nab- paclitaxel plus gemcitabine is an active and well tolerated regimen even in pretreated patients.

Keywords: CA19.9, clinical benefit, gemcitabine, metastatic pancreatic cancer, nab- paclitaxel.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [142 - 145]
Pages: 4
DOI: 10.2174/1574887110666150417115303
Price: $58

Article Metrics

PDF: 37